Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Decoy Therapeutics says preclinical pharmacokinetic results show a single weekly intranasal dose could sustain protective exposure across upper airways and lungs for about a week; clinical trials expected to begin in 2027, with data scheduled for Sept 29 presentation.
Decoy Therapeutics said a single intranasal dose maintained drug concentrations above designed therapeutic levels for up to seven days in nasal mucosa and lung tissue, with extended tissue retention supporting prophylaxis for high-risk patients. The company expects the DCOY-CoV program to enter clinical trials in 2027.
TradeXchange Newsdesk says Decoy Therapeutics (DCOY) reported preclinical data supporting once-weekly intranasal dosing for its DCOY-CoV program.